Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited’s SEC filings document its foreign private issuer disclosures and ASX announcements furnished on Form 6-K. The filings include half-year financial reports, strategic updates and investor presentations describing the company’s oral polyclonal antibody platform, Hyper-Immune products, Travelan®, ProIBS®, and clinical programs for gastrointestinal infectious diseases.
The filing record also covers shareholder meeting results, small-holding share sale facility disclosures, R&D Tax Incentive notices, regional sales updates, and governance authorizations by the board. These documents provide formal disclosures on operating results, research and development funding, ordinary-share matters, and public-company reporting obligations for IMRN’s ASX and Nasdaq-traded securities.
Immuron Limited is an Australian biopharmaceutical company developing orally delivered polyclonal antibodies for infectious, gut-mediated diseases. The chief executive officer presented an investor update at the TechKnow Invest Roadshow in Melbourne, outlining recent commercial performance, cash position and partnering plans for its clinical assets.
For FY 2026, global sales revenue was A$7.7 million, up 6% on the prior year, including Australian sales of A$5.8 million (up 10%), U.S. sales of A$1.8 million (up 7%, or 13% in USD), and Canadian sales of A$0.2 million (down 55%). HY 2026 EBITDX (ex‑R&D) was -A$1.1 million, and cash was A$10.0 million at 31 December 2025, described as equivalent to 22.5 months of cash used in operating activities in 1H FY26; an A$1.1 million R&D tax incentive was received in February 2026.
The company markets Travelan for travelers’ diarrhea and ProIBS for irritable bowel syndrome while pursuing partnerships for IMM‑124E and IMM‑529. IMM‑124E (Travelan) is eligible for an end‑of‑Phase 2 FDA meeting, and IMM‑529 for Clostridioides difficile infection has an FDA‑approved investigational new drug application and preclinical survival rates around 80–90% in prevention, treatment and relapse models. Management highlights a strategy to partner these assets, reduce net R&D expense, and focus internal resources on over‑the‑counter sales and portfolio expansion.
Immuron Limited reports that CEO Steven Lydeamore will present at the TechKnow Invest Roadshow in Melbourne on July 27, 2026.
The Australian biopharmaceutical company develops orally delivered targeted polyclonal antibodies, including Travelan for travelers’ diarrhea and IMM-529 for recurrent Clostridioides difficile infection. Its platform uses hyperimmune bovine colostrum to generate antibodies active in the gastrointestinal tract, and it also distributes ProIBS for irritable bowel syndrome in Australia and New Zealand, citing supporting clinical and market data.
Immuron Limited, an Australian biopharmaceutical company focused on orally delivered polyclonal antibodies for infectious and gut-mediated diseases, reported FY26 global sales revenue of A$7.7 million, up 6% on the prior year. Australian sales were A$5.8 million, up 10%, and U.S. sales were A$1.8 million, up 7% (13% in USD), while Canadian sales were A$0.2 million, down 55% with strong growth in 4Q FY26. HY26 EBITDX (ex-R&D) was a loss of A$1.1 million, but improved versus both HY25 and 2H FY25. Cash was A$10.0 million at 31 December 2025, equivalent to more than 22 months of 1H FY26 operating cash use, supported by a A$1.1 million R&D Tax Incentive.
Immuron markets two oral products, Travelan for travelers’ diarrhea risk reduction and ProIBS for irritable bowel syndrome symptoms, generating four consecutive quarters of Travelan sales above the prior year. The company is pursuing a partnering strategy for its clinical assets IMM-124E (eligible for an end of Phase 2 meeting with the U.S. FDA for travelers’ diarrhea) and IMM-529 (oral biologic for C. difficile infection with an FDA-approved IND for Phase 2). Under this model, partners would typically fund development and commercialization in exchange for upfront payments, milestones and royalties, aiming to reduce Immuron’s R&D spend and cash burn while it focuses on over-the-counter commercialization and expanding its distribution and product portfolio.
Immuron Limited reports unaudited FY26 Travelan sales of AUD$7.7 million, up 6% on the prior comparative period, marking four consecutive quarters of growth. Second-half sales were AUD$3.5 million, up 7%, and fourth-quarter sales were AUD$2.0 million, up 2%.
Australia remained the largest market with FY26 sales of AUD$5.8 million, up 10% on pcp, supported by expanded digital marketing, new store listings, and increased South East Asian travel. U.S. FY26 sales reached AUD$1.8 million (USD$1.2 million), up 7% in AUD and 13% in USD, aided by Amazon enhancements and social media campaigns, partly offset by a stronger Australian dollar.
Canada delivered FY26 sales of AUD$0.2 million, down 55% on pcp after a prior-year pipeline fill, but quarterly trends improved, with Q4 FY26 sales up 427% on pcp as promotions and in‑store education built brand awareness. Immuron also outlines its antibody-based platform programs IMM-124E (Travelan), IMM-529 for recurrent C. difficile infection, and distribution of ProIBS for irritable bowel syndrome.
Immuron Limited has engaged life sciences advisory firm Pullan Consulting to help secure a strategic partnership for its IMM-529 program targeting Clostridioides difficile infection (CDI). Pullan has executed between five and twelve partnering transactions annually over the past 20 years.
IMM-529 has FDA Investigational New Drug approval for a Phase 2 trial in CDI, with a planned randomized, double-blind, placebo-controlled study of up to 60 subjects at multiple Australian sites under the fast-track Clinical Trial Notification scheme. An opportunity assessment projects base case yearly revenue of about US$400M if IMM-529 proves efficacious and gains favorable positioning in the treatment algorithm. Preclinical models showed strong prevention and treatment effects, and Immuron is seeking a licensee to fund further development, registration, and commercialization through a typical structure of upfront fees, milestones, and royalties.
Immuron Limited reports that 3,805,528 IMC ordinary fully paid shares have ceased on the ASX as of 29/6/2026. The company paid consideration of AUD 0 per security for this cessation.
After this change, Immuron has 322,848,081 IMC ordinary fully paid shares on issue, along with 3,767,492 IMCAE performance rights and 8,000,000 IMCAI options expiring on various dates at various prices. These figures will be used by the ASX to calculate the company’s market capitalization.
Immuron Limited has completed its small holding share sale facility, buying back 3,805,528 ordinary shares at $0.032 per share, for an aggregate value of $121,777. These shares will be cancelled.
The facility targeted shareholders holding less than a marketable parcel, defined under ASX rules as shares worth under $500 based on the 8 April 2026 record date price. Eligible shareholders could opt out or top up their holdings; those who did not became participating shareholders whose shares were acquired under the buy-back.
Following completion, Immuron’s ordinary shares on issue decreased from 326,653,609 to 322,848,081, and the number of shareholders fell from 2,264 to 1,253. The company expects this to lower ongoing administrative costs associated with managing many very small holdings.
Immuron Limited filed a Form 6-K noting the expiry of a tranche of options listed on the ASX. On 18 June 2026, 1,430,000 IMCAI options expiring on various dates and at various exercise prices ceased after expiring without being exercised or converted, and no consideration was paid for the cessation.
Following this lapse, Immuron reports issued capital of 326,653,609 ordinary fully paid shares, along with 3,767,492 performance rights and 8,000,000 IMCAI options still on issue, as recorded in the ASX-generated tables.
Immuron Limited furnished a Form 6-K providing its response to an ASX price query about recent trading in its securities. The company states it is not aware of any information that has not been announced which would explain the price movements and confirms it remains in compliance with ASX Listing Rule 3.1 on continuous disclosure. The response notes a previously disclosed CEO presentation at the Emerging Growth Conference and has been authorised by the Board of Directors.
Immuron Ltd executive Flavio Palumbo has filed an initial ownership report showing his equity interests in the company. He directly holds 1,142,909 Ordinary Shares. He also holds 640,824 Performance Rights, each linked to Ordinary Shares, with a zero exercise price and an expiration date of June 30, 2029. These performance rights vest only when specified non-market key performance indicators and performance milestones are achieved, after which they can be exercised any time until expiration.